Dogwood Therapeutics DWTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -64.6%— | —— | -931%-437pp | -494.1%-42.8pp | -451.3%— | |
| Return on assets | -29.5%+7.7pp | -37.1%+43.9pp | -81%-31.7pp | -49.3%-5.4pp | -43.9%-18.8pp | |
| Liquidity | ||||||
| Current ratio | 5.9×+3.1× | 2.8×-1.7× | 4.5×-3.3× | 7.8×+0.4× | 7.4×+2.2× | |
| Quick ratio | 5.9×+3.1× | 2.8×-1.7× | 4.5×-3.3× | 7.8×+0.4× | 7.4×+2.2× | |
| Cash ratio | 5.2×+3.0× | 2.1×-1.8× | 3.9×-3.2× | 7.1×+0.3× | 6.8×+2.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -89×+199× | -288.5×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $2.40-84.0% | $15.05+298% | $3.78+5.1% | $3.60-26.8% | $4.92+150% | |
| Valuation | ||||||
| Market capitalization | $54.14M-57.6% | $123.67M-46.0% | $228.9M+90.5% | $120.16M-3.2% | $124.12M+189% | |
| Enterprise value | $41.06M-64.7% | $117.31M-46.4% | $218.95M+105% | $106.94M+0.2% | $106.78M+277% | |
| Price / book | 0.6×-16.6× | 1.7×-29.9× | 31.5×+14.1× | 17.5×0.0× | 17.5×— | |
| Earnings yield | -56.5%-35.6pp | -27.7%-11.0pp | -16.7%+3.9pp | -20.6%-2.9pp | -17.7%+11.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Dogwood Therapeutics's ratios come from?
- Every ratio is computed from Dogwood Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.